Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
CONCLUSION: GLP-1 RA therapy in the context of individualized, patient-centered care continues to be supported by current literature. GLP-1 RA therapy provides robust glycemic control, blood pressure reduction, and weight loss, but studies are still needed to address concerns about tolerability and safety, including pancreatitis and cancer.
PMID: 26694823 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - Category: Endocrinology Authors: Drab SR Tags: Curr Diabetes Rev Source Type: research
More News: Byetta | Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Pancreas | Pancreatic Cancer | Pancreatitis | Study | Thyroid | Thyroid Cancer | Victoza | Weight Loss